Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:RNLX Renalytix (RNLX) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsEarningsHeadlinesOwnershipShort InterestTrends About Renalytix Stock (NASDAQ:RNLX) 30 days 90 days 365 days Advanced Chart Get Renalytix alerts:Sign Up Key Stats Today's Range$0.19▼$0.2350-Day Range$0.18▼$0.3052-Week Range$0.18▼$2.40Volume934,400 shsAverage Volume1.45 million shsMarket Capitalization$17.18 millionP/E RatioN/ADividend YieldN/APrice Target$3.00Consensus RatingBuy Company OverviewRenalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record systems to generate a unique patient risk score. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. Renalytix Plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; and Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers. The company also has a partnership agreement with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to implement an advanced clinical care model designed to improve kidney health and reduce kidney disease progression and kidney failure. The company was formerly known as Renalytix AI plc and changed its name to Renalytix Plc in June 2021. Renalytix Plc was incorporated in 2018 and is based in New York, New York.Read More… Receive RNLX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Renalytix and its competitors with MarketBeat's FREE daily newsletter. Email Address RNLX Stock News HeadlinesRenalytix Adjusts Share Capital Amid Fundraising ShortfallNovember 6, 2024 | markets.businessinsider.comRenalytix and Steno Diabetes Center Announce Precision Medicine Collaboration Marking First Expansion for KidneyIntelX Platform Beyond USJuly 11, 2024 | globenewswire.comTrump’s $500 Billion AI Move—How You Could ProfitWith Trump's recent AI announcement, a MASSIVE opportunity has opened up for investors. A $500 billion plan is set to reshape America's tech landscape, involving big players like OpenAI, Oracle, and SoftBank. But here's the best part... For as little as $20, you have the opportunity to get in on this revolutionary project... By investing in an under-the-radar company, set to benefit greatly from this massive AI expansion.February 10, 2025 | Behind the Markets (Ad)Renalytix Submits Hearing Request to Nasdaq Hearings Panel in Regard to Staff Delisting DeterminationJune 27, 2024 | globenewswire.comMedicare Issues Final Coverage Determination for kidneyintelX.dkdJune 14, 2024 | globenewswire.comRNLX Stock Earnings: Renalytix Misses EPS, Misses Revenue for Q3 2024May 15, 2024 | investorplace.comRenalytix AI GAAP EPS of -$0.08 beats by $0.01, revenue of $0.54M misses by $0.56MMay 15, 2024 | msn.comRenalytix Reports Financial Results for Third Quarter of Fiscal Year 2024May 15, 2024 | globenewswire.comSee More Headlines RNLX Stock Analysis - Frequently Asked Questions How were Renalytix's earnings last quarter? Renalytix Plc (NASDAQ:RNLX) announced its quarterly earnings results on Tuesday, November, 14th. The company reported ($0.11) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.11). The firm earned $0.46 million during the quarter, compared to the consensus estimate of $0.70 million. When did Renalytix IPO? Renalytix (RNLX) raised $156 million in an initial public offering on Friday, July 17th 2020. The company issued 11,000,000 shares at a price of $14.22 per share. J.P. Morgan and Stifel served as the underwriters for the IPO. What other stocks do shareholders of Renalytix own? Based on aggregate information from My MarketBeat watchlists, some other companies that Renalytix investors own include Invesco QQQ (QQQ), SPDR Dow Jones Industrial Average ETF Trust (DIA), SPDR S&P 500 ETF Trust (SPY), NVIDIA (NVDA), CrowdStrike (CRWD), Broadcom (AVGO) and Meta Platforms (META). Company Calendar Last Earnings11/14/2023Today2/09/2025Fiscal Year End6/30/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorComputer and Technology Industry Medical laboratories Sub-IndustryHealthcare Current SymbolNASDAQ:RNLX CUSIPN/A CIK1811115 Webwww.renalytixai.com Phone44-20-3139-2910FaxN/AEmployees100Year FoundedN/APrice Target and Rating Average Stock Price Target$3.00 High Stock Price Target$3.00 Low Stock Price Target$3.00 Potential Upside/Downside+1,348.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.39) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-33,460,000.00 Net Margins-1,461.60% Pretax Margin-1,461.42% Return on EquityN/A Return on Assets-281.40% Debt Debt-to-Equity RatioN/A Current Ratio0.53 Quick Ratio0.53 Sales & Book Value Annual Sales$2.29 million Price / Sales7.50 Cash FlowN/A Price / Cash FlowN/A Book Value($0.10) per share Price / Book-2.07Miscellaneous Outstanding Shares82,960,000Free Float63,059,000Market Cap$17.18 million OptionableOptionable Beta2.72 Social Links A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for February 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free Report This page (NASDAQ:RNLX) was last updated on 2/10/2025 by MarketBeat.com Staff From Our PartnersJapanese billionaire pledges $500 billion to Trump’s AmericaJapanese billionaire Masayoshi Son calls it “the beginning of America’s golden age.” But I call it, “you’re...Porter & Company | SponsoredBig Tech’s $17 Trillion Reckoning DayThe world's biggest tech companies are silently sounding the alarm. While everyday investors keep piling in...InvestorPlace | SponsoredDeFi Coin on Verge of Breakout!The blueprint for millionaires is here. Don't let this be the missed opportunity you regret for years. Crypto 101 Media | SponsoredBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredThe Secret Winner in Trump’s AI RevolutionTrump just announced a $500 billion plan to revolutionize artificial intelligence. He's calling it The Star...Behind the Markets | SponsoredTop 5 Trump Stocks for His First 100 DaysRight now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | SponsoredSteve Bannon Sounds Alarm On Elon Musk’s ‘Indefensible Betrayal’Now, if Elon Musk was truly an America First champion… His cronies wouldn't be bragging to the New York Tim...Colonial Metals | SponsoredElon’s ‘Agents’ StrikeHe might be the richest man on the planet – but Elon Musk just landed himself a new job... In a move that c...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Renalytix Plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Renalytix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.